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ABSTRACT
Introduction: Allogeneic hematopoietic stem cell transplantation (alloHSCT) offers potential curative
treatment for a wide range of malignant and nonmalignant hematological disorders. However, its
success may be limited by post-transplant acute graft-versus-host disease (aGVHD), a systemic syn-
drome in which donor’s immune cells attack healthy tissues in the immunocompromised host. aGVHD
is one of the main causes of morbidity and mortality after alloHSCT. Despite standard GVHD prophylaxis
regimens, aGVHD still develops in approximately 40–60% of alloHSCT recipients.
Areas covered: In this review, after a brief summary of current knowledge on the pathogenesis of
aGVHD, the authors review the current combination of a calcineurin inhibitor with an antimetabolite
with or without added anti-thymocyte globulin (ATG) and emerging strategies for GVHD prevention.
Expert opinion: A new understanding of the involvement of cytokines, intracellular signaling pathways,
epigenetics and immunoregulatory cells in GVHD pathogenesis will lead to new standards for aGVHD
prophylaxis allowing better prevention of severe aGVHD without affecting graft-versus-tumor effects.
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1. Introduction
Allogeneic hematopoietic stem cell transplantation (alloHSCT)
offers potential curative treatment for a wide range of hema-
tological disorders.[1] In patients with hematological malig-
nancies, tumor eradication depends both on the
conditioning regimen given before alloHSCT, and on graft-
versus-tumor effects mediated by donor immune cells (mainly
T cells) contained in the graft.[2] Several conditioning regi-
mens have been developed ranging from high-dose myeloa-
blative regimens to reduced-intensity conditioning (RIC) or
truly nonmyeloablative conditionings.[3,4] Myeloablative con-
ditionings result in complete ablation of host hematopoiesis.
Nonmyeloablative and RIC regimens exert only moderate
myelosuppression but provide sufficient immune suppression
to allow sustained donor T-cell engraftment and tumor eradi-
cation through graft-versus-tumor effects. They have been
developed to reduce transplant-related mortality, allowing to
perform alloHSCT in older patients and in those with medical
comorbidities.
Three different sources of stem cells can be used for
alloHSCT: bone marrow (BM), granulocyte-colony stimulating
factor (G-CSF) mobilized peripheral blood stem cells (PBSCs),
and umbilical cord blood (UCB).[5] The ideal donor is a human
leukocyte antigen (HLA)-identical sibling. When such a donor is
not available, alternative donors can be HLA-matched or 1–2/10
HLA-mismatched unrelated donors, HLA-haploidentical-related
(haplo) donors (mismatched for 1 of the 2 HLA haplotypes), or
UCB. While outcomes after alloHSCT with HLA-matched unre-
lated donors are currently similar to those achieved with HLA-
identical siblings, HLA-mismatched alloHSCT as well as UCB-
alloHSCT remain associated with higher transplant-related and
mortality.[5] HLA-haploidentical alloHSCT has historically been
limited by high transplant-related mortality.[6] However, several
recent approaches, including effective ex vivo and in vivo T-cell
depletion strategies (see later), enabled achieving very favor-
able outcomes in that setting.[6]
Although donor T cells contained in the graft are the main
driver of graft-versus-tumor effects, they can also mediate
harmful damages to host healthy tissues causing graft-ver-
sus-host disease (GVHD). GVHD is one of the main complica-
tions of alloHSCT. GVHD has been historically separated into
two syndromes: acute GVHD (aGVHD), occurring within 100
days after transplantation, and chronic GVHD (cGVHD) devel-
oping thereafter. This classification was simple but did not rely
on actual biological or clinical bases. Currently, it is widely
accepted that aGVHD and cGVHD have specific clinical pre-
sentation and pathogenesis.[7–9] In this article, we will focus
on aGVHD.
Clinically, aGVHD manifests as strong inflammatory lesions
mainly of the skin, gut, and liver. AGVHD can be scored from
grade I to IV, according to the severity of organ signs and
dysfunctions.[10] Clinically significant grade II–IV aGVHD is a
major cause of transplant-related morbidity after alloHSCT
while mild aGVHD (grade I) is associated with better survival
due to lower risk of disease relapse (translating higher graft-
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versus-tumor effects).[11–13] Thymic and BM niches can also
be significantly damaged by aGVHD,[14,15] further compro-
mising efficient T- and B-cell reconstitution and predisposing
patients to cGVHD.[16] Hence, prevention strategy to avoid
aGVHD occurrence remains a major challenge of alloHSCT.[17]
2. Pathogenesis of aGVHD
AGVHD immunopathophysiology is complex. Insights from
experimental models and clinical translational research have
enabled the identification of a complex immune network of
triggers, sensors, mediators and effectors of aGVHD reactions,
as well as tolerogenic actors that can mitigate the process.
[7,8,17–20] Here is presented a brief summary of some key
mechanisms, in the attempt to better understand the rationale
of novel approaches for aGVHD prevention (Figure 1).
It is commonly accepted that aGVHD results from the
detection of host disparate antigens by donor T cells. The
primordial role of T cells in aGVHD pathogenesis is demon-
strated by the low incidence of GVHD observed in patients
given T-cell depleted alloHSCT.[21] Under most circumstances,
including aGVHD, adaptive T-cell responses are primed by the
innate immune system. By expressing pattern recognition
receptors (such as Toll-like and nucleotide oligomerization
domain (NOD)-like receptors), innate immune cells may
recognize danger signals released by damaged tissues
Article highlights
● Three randomized studies have demonstrated that ATG (combined
with CSA and MTX) might be the new standard of care for patients
transplanted with HLA-matched PBSC.
● New understanding of aGVHD pathogenesis has led to the develop-
ment of new targets for aGVHD prophylaxis.
● Most promising pharmacological approaches include post-transplant
Cy administration, JAKs inhibitors, HDAC inhibitors, bortezomib,
hypomethylating agents, as well as IL-6 blockade.
● Most promising cellular approaches include co-transplantation of
Tregs.
● Risk-stratification directed strategies for aGVHD prevention will likely
help to improve aGVHD-related morbidity and mortality.
This box summarizes key points contained in the article
Figure 1. Targets of standard and emerging therapies for the prevention of aGVHD.
Events presented on the left side of the central discontinued grey line mostly occur in peripheral tissues, whereas those presented on the right side mostly occur in
secondary lymphoid organs.
Sites of action of standard prophylaxis regimens are depicted in circles (A = methotrexate; B = calcineurin inhibitors; C = mycophenolate mofetil) while sites of
action of emerging strategies are depicted in losanges (1 = proteasome inhibitors, 2 = CTLA4-Immunoglobulin; 3 = mTOR inhibitors; 4 = JAK inhibitors;
5 = hypomethylating agents; 6 = histone deacetylase inhibitors; 7 = Cytokine antagonists, such as anti-IL-6 receptor antibody; 8 = homing receptor antagonists,
such as anti-CCR5; 9 = strategies aiming at decreasing the production of DAMPs or PAMPs, such as modulation of gut microbiota or alpha-1 anti-trypsine
supplementation. Note that hypomethylating agents and histone deacetylase inhibitors can also act as epigenetic modulators in other immune cells than CD4+ T
cells, such as in CD8+ T cells, Tregs, and APCs. Concerning JAK/STAT pathways, STAT3 is a key transcription factor for type 17 cell differentiation whereas STAT4 and
STAT6 are more implicated in type 1 and type 2 T-cell differentiation, respectively.
Ac: acetyl; APC: antigen-presenting cell; DAMPs: damage-associated molecular patterns; HLA: human leukocyte antigen; IL: interleukin; IL-2R: IL-2 receptor; M:
methyl; miHAg: minor histocompatibility antigen; NK cells: Natural killer cells; P: phosphate; PAMPs: pathogen-associated molecular patterns; TCR: T-cell receptor;
TYK2: tyrosine kinase 2; Ub: ubiquitine.





























(damage-associated molecular patterns [DAMPs]) and/or by
pathogens (pathogen-associated molecular patterns [PAMPs])
that further activate them. In humans, single nucleotide poly-
morphisms of some pattern recognition receptors (such as
NOD-like receptor NOD2/CARD15 variants) in the recipient
and/or the donor have been reported to be associated with
aGVHD.[22] Further, several DAMPs and PAMPs have also been
identified in aGVHD. The most well known are heparan sulfate
(an extracellular matrix component), adenosine triphosphate
(ATP) and uric acid (both released by dying cells), and lipopo-
lysaccharide (mostly from the gut microbiota). These mole-
cules can be released during conditioning regimen. In this
way, conditioning regimens may prime host innate immune
cells before donor T-cell infusion.
There is also increasing evidence of roles of the commensal
microbiota in aGVHD pathophysiology. Indeed, several studies
demonstrated that early microbiome shifts and loss of micro-
biome diversity after alloHSCT were associated with higher
risks of aGVHD.[23–25]
Activated antigen presenting cells (APCs) present host
alloantigens on HLA molecules to donor T cells. They also
provide them costimulatory signals that are necessary to
induce their proliferation and differentiation after T-cell recep-
tor (TCR) activation by antigens. In most cases, TCR stimulation
without second signal through costimulatory molecules leads
to T-cell anergy. Many costimulatory ligand/receptor interac-
tions have been reported to be involved in aGVHD.[26] The
most extensively studied involve interactions between B7
molecules (CD80 and CD86) on APCs and CD28 on T cells, as
well as between CD40 on APCs and CD40 ligand on activated
T cells. The former create a more complex system, with both
positive (B7: CD28) and inhibitory (B7: cytotoxic T lymphocyte
antigen 4 (CTLA-4)) pathways. T-cell activity may also be
counter-regulated by inhibitory molecules, such as pro-
grammed cell death protein 1 (PD1). Finally, APCs provide a
third proliferative signal to alloreactive T cells through the
release of cytokines, such as IL-7 and IL-15, and are also
implicated in helper T (Th) cell polarization.[27]
Interactions between T cell and APC trigger multiple and
complex intracellular signaling pathways in both cells. In T cell,
TCR stimulation induces calcium-dependent signal transduc-
tion leading to the activation of calcineurin. Calcineurin
dephosphorylates the nuclear factor of activated T cell
(NFAT) proteins and enables their import to the nucleus,
where they induce transcription of interleukin (IL)-2 and
other cytokines that ultimately lead to T-cell proliferation.
The nuclear factor kappa B (NFκB) pathway is also activated
downstream to TCR stimulation. NFκB is normally located in
the cytosol in an inactivated state, complexed with the inhibi-
tory protein IκBα. TCR activation induces phosphorylation of
IκBα, which results in its ubiquitination and degradation by
the proteasome. Dissociated from IκBα, activated NFκB then
translocates into the nucleus where it binds to specific
sequences of DNA leading to transcription of cytokines (pre-
dominantly IL-2), the high-affinity IL-2 receptor (CD25), and of
costimulation molecules. Hence, T-cell activation through TCR
leads to the autocrine secretion of IL-2 and to the expression
of IL-2 receptor. IL-2 is a key cytokine for T-cell proliferation,
differentiation, and survival. The stimulation of IL-2 receptor at
the surface of activated conventional T cells (Tconvs) can
activate the mammalian target of the rapamycin (mTOR) as
well as Janus kinases (JAK) and signal transducers and activa-
tors of transcription (STAT) (precisely JAK1/STAT5 and JAK3/
STAT5), which both regulate cell cycle and lead to T-cell pro-
liferation. JAK/STAT pathways may also be critical for deter-
mining T-cell differentiation (Figure 1).[28] Further,
importantly, the mTOR pathway is constitutively inactivated
in regulatory T cells (Tregs), that depends mainly on the STAT5
pathway for signaling upon IL-2 receptor stimulation.[29]
Both donor CD4+ and CD8+ T cells are crucial in the patho-
genesis of GVHD. Studies in mice suggested that naive T cells
are the primary drivers of aGVHD reactions, while effector
memory T cells are less prone to mediate GVHD but partici-
pate in transfer of anti-pathogen functional memory.[30] Naive
T cells can differentiate into various lineages (such as the well-
established type 1, type 2, and type 17 T-cell lineages) in the
presence of specific cytokines (i.e. IL-12, IL-4, and IL-6, respec-
tively). Recent data suggest that aGVHD within individual
organs is preferentially generated by specific T-cell subsets,
in part because of their respective chemokine profiles and the
relative sensitivity of targeted tissues to their effector cyto-
kines. Specifically, type 1 cells seem to be preferentially impli-
cated in gastrointestinal, type 2 cells in cutaneous and hepatic,
and type 17 cells in cutaneous and pulmonary aGVHD.
[18,31,32] Newly identified T-cell subsets (including type 9,
type 22, and T follicular helper cells) add further complexity.
Tissue homing molecules and receptors are important in
aGVHD immunobiology, since they orchestrate alloreactive
T-cell (as well as Treg) trafficking toward target organs.[33]
Among them, CCR5 was reported to be involved in T-cell
migration to both lymph nodes and gastrointestinal tract in
murine models.
Activated APCs and T cells initiate an immune response and
a cytokine storm that further recruit additional immune cells,
amplifying the phenomenon and leading to the effector phase
of aGVHD in target organs. The effector phase involves cellular
effectors (such as cytotoxic CD8+ T cells, natural killer (NK)
cells, neutrophils, and activated macrophages) and inflamma-
tory molecules (mainly IL-1β, tumor necrosis factor-alpha (TNF-
α), interferon-gamma (IFN-γ) and reactive oxygen species) that
lead to antigen-dependent and -independent destruction of
host tissues. It is well demonstrated that regulatory/tolero-
geneic cells can control this destructive machinery of immune
cells. Intense investigations have focused on Tregs. Tregs
represent a fraction of CD4+ T cells that are indispensable for
maintaining immunological self-tolerance.[34,35] They express
the forkhead box protein 3 factor (FoxP3) in their nuclei, and
CD25 (the high-affinity component of the trimeric form of the
IL-2 receptor) on their surface.[34,35] Tregs are also featured
by a dependency on IL-2 for their homeostasis.[35,36]
Importantly, several studies have demonstrated that Treg co-
transplantation at a Treg/CD4+Tconv ratio of 1/1 or 1/2 pre-
vented aGVHD in mouse to mouse [37,38] as well as in huma-
nized mice [39,40] models of aGVHD. In humans, Treg infusion
also resulted in promising results for preventing aGVHD (see
later).
Mesenchymal stem cells (MSCs) are multipotent progenitor
cells with fibroblastic-like morphology that exert several





























immunomodulatory effects on both adaptive and innate
immune cells.[41–43] MSC can inhibit T-cell proliferation by
secretion of soluble mediators (i.e. TGF-β, IL-10, IDO, etc.) and
by cell contact interactions with molecules expressed on their
surface (i.e. PD1–ligand, etc.). Furthermore, MSC might also
promote the generation of tolerogenic dendritic cells and of
Tregs. Finally, MSC are hypoimmunogenic, allowing transfer
across HLA barriers.
Several other cells have also been reported to mitigate
GVHD, such as invariant natural killer T (iNKT) cells,[44–46]
myeloid-derived suppressor cells (MDSCs),[47,48] and more
recently CD34+ regulatory monocytes.[49]
Finally, controversies still remain about implication of B
cells in the pathogenesis of aGVHD, with data from preclinical
and clinical studies showing both potential pathogenic as well
as protective effects.[50] In mice, the B-cell protective activity
appears to be mediated by their secretion of IL-10. Recently,
impairment in IL-10-producing B cells (regulatory B cells, Breg)
was also described in patients with cGVHD.[51]
3. Current approaches for aGVHD prevention
3.1. Standard approaches: antimetabolites and
calcineurin inhibitors
Since the 1980s, standard GVHD prophylaxis for patients given
myeloablative alloHSCT from HLA-matched sibling or unre-
lated donor has consisted of the combination of the folate
antagonist methotrexate (MTX, which deletes proliferating
lymphocytes) with a calcineurin inhibitor (either cyclosporin
A, CSA or tacrolimus, FK506, tacro).[52,53] There is no consen-
sus about what it the best calcineurin inhibitor between CSA
and tacro. Compared to the association of MTX and CSA, the
combination of MTX and tacro is associated with a 40% lower
risk of aGVHD, but similar incidence of cGVHD and comparable
mortality.[54] Mycophenolate mofetil (MMF) has also shown
synergistic activities with calcineurin inhibitors for preventing
aGVHD.[55] Its metabolite, mycophenolic acid, inhibits lym-
phocyte proliferation by blocking de novo synthesis of guano-
sine nucleotides. MMF is currently commonly used instead of
MTX in combination with either CSA or tacro for GVHD pro-
phylaxis in the settings of nonmyeloablative/RIC-alloHSCT
[52,56,57] and UCB-alloHSCT.[58] Although GVHD prevention
does not seem to be improved by the use of MMF rather than
MTX in RIC-alloHSCT, MMF-based regimens have demon-
strated a more favorable toxicity profile.[52,56] Further, in
the UCB-alloHSCT setting, the combination of CSA and MMF
is associated with a lower incidence of cGVHD than the asso-
ciation of CSA and steroids.[58] Mechanisms of action of these
standard molecules are schematized in Figure 1.
3.2. T-cell depleting approaches
Although combinations of calcineurin inhibitors with MTX or
MMF have been relatively successful at preventing the most
severe forms of aGVHD, these regimens are not uniformly
effective and mostly fail to prevent the development of mod-
erate/severe cGVHD, particularly after alloHSCT with PBSC or
with unrelated donors.[59,60] This prompted number of
groups to investigate the addition of pre-transplant anti-T-
cell antibodies to standard prophylaxis regimens, in the
attempt to induce in vivo depletion of donor T cells. Anti-T-
cell globulins (ATG) are polyclonal IgG antibody preparations
from horses or rabbits (the later being the most frequently
used for GVHD prevention) that were immunized with human
thymocytes or the T-cell line Jurkat. Rabbit ATG induces in vivo
T-cell depletion through several cell-death mechanisms (com-
plement-dependent lysis and activation-associated apoptosis)
and induce the generation of Tregs.[29,61] Several studies
have reported that ATG more specifically induces profound
and prolonged depletion in the naive compartment of T cells.
[46,62] Three phase III randomized trials have reported that
pre-transplant ATG successfully decreased the incidence of
both a- and cGVHD without increasing the risk of relapse
after myeloablative alloHSCT with related [63] or unrelated
PBSC.[64,65] In RIC setting, the role of ATG has not been
formally established yet. Indeed one registry study including
data from patients transplanted for various hematological
malignancies found a higher risk of relapse and of overall
mortality in patients given ATG,[66] while another study focus-
ing on patients with acute myeloid leukemia given PBSC from
HLA-identical siblings found lower incidence of cGVHD but
similar risks of relapse and mortality in patients given ATG in
comparison to patients not given in vivo T-cell depletion.[67]
Finally, recent reports have observed that ATG increased the
risks of infection and mortality after UCB-alloHSCT.[68,69]
In vivo T-cell depletion with alemtuzumab, a humanized
anti-CD52 IgG1 monoclonal antibody with both T- and B-cell-
depleting properties, has also been studied, mostly in the
setting of RIC-alloHSCT.[70,71] CD52 antigen is expressed on
T, NK, and B cells, but not on hematopoietic stem cells. Pre-
transplant infusion of alemtuzumab was shown to very effi-
ciently prevent both a- and cGVHD.[66,67,70,71] However,
potential limitations of alemtuzumab included delayed
immune recovery, increased risk of infections, delayed
achievement of full donor T-cell chimerism and the need to
give pre-emptive donor lymphocyte infusions to prevent dis-
ease relapse in patients with persisting mixed donor chimer-
ism or with evidence of minimal residual disease. One registry
study including data from patients transplanted for various
hematological malignancies found a higher risk of relapse
and of overall mortality in patients given alemtuzumab com-
pared to patients not given in vivo T-cell depletion,[66] while
another study focusing on patients with acute myeloid leuke-
mia given PBSC from HLA-identical siblings found lower inci-
dence of cGVHD but similar risks of relapse and mortality in
patients receiving alemtuzumab compared to patients not
given in vivo T-cell depletion.[67]
In a related approach, ex vivo T-cell depletion of the graft
has been evaluated to prevent GVHD. Although initial studies
in BM-alloHSCT suggested that the beneficial effect of such an
approach on GVHD prevention was offset by increased rates of
graft failure, relapse, and infections,[72] two multicenter pro-
spective phase II trial with PBSC as stem cell source, and with
optimized techniques for ex vivo T-cell depletion (i.e. immu-
nomagnetic positive CD34+ cell selection) have suggested that
this strategy efficiently prevented GVHD without apparently
increasing the relapse incidence.[73,74] However, large





























randomized studies are needed before this approach might
become a standard of care for GVHD prophylaxis in the HLA-
matched setting, and specifically to assess the impact of pro-
found T-cell depletion of the graft on the incidence of relapse.
Finally, infusion of megadoses of purified CD34+ cells has been
the basis for T-cell depleted HLA-haploidentical transplanta-
tion approaches.[21,75]
4. Novel approaches for aGVHD prevention
Despite GVHD prophylaxis with standard regimens, aGVHD
still develops in approximately 40–60% of patients after
alloHSCT, underlying the need for developing new approaches
aimed at better preventing aGVHD. It is the matter of intense
research since several years. Considering the large body of
recent work in this field, citing all original studies in this review
is elusive. Here, we are reviewing only a selection of them,
which we feel are the most promising.
4.1. T-cell depleting approaches
4.1.1. Depletion of donor T cells
As mentioned in Table 1, strategies for in vivo lymphocyte
depletion with ATG or alemtuzumab are now recognized as
potent approaches to prevent both a- and cGVHD. Other anti-
T-cell antibodies, such as anti-CD3 or anti-CD2 monoclonal
antibodies (visilizumab and siplizumab, respectively) are cur-
rently under investigation (ClinicalTrials.gov#NCT00113646
with siplizumab), but does not seem to be superior to rabbit
ATG for aGVHD prevention (#NCT00720629).
Pentostatin, a purine analog, may also induce in vivo lym-
phocyte depletion through inhibition of adenosine deaminase
(ADA), thereby leading to lymphocyte apoptosis due to the
cytotoxic accumulation of deoxyadenosine triphosphate. Since
ADA enzymatic activity is greater in T cells than in B cells,
pentostatin mostly depletes the T-cell compartment. Recently,
a phase I–II controlled study was performed where patients
undergoing unrelated or mismatched related donor alloHSCT
received increasing doses (0–2 mg/m2) of post-transplant pen-
tostatin (on days 8, 15, 22, and 30 after alloHSCT) in combina-
tion with tacro/MTX for GVHD prevention.[76] The lowest
aGVHD incidence was observed in patients receiving the
1.5 mg/m2 dosing regimen (35.7% versus 55.6% in patients
who did not receive pentostatin, P = 0.085).
Other approaches for deleting donor T cells in case of
aGVHD rely on engineering T cells through the expression of
suicide genes before their infusion into patients. Hence, if
GVHD occurs, the in vivo selective destruction of donor T
cells may be pharmacologically induced by specific molecules.
The advantage of this technique is that it allows the occur-
rence of T-cell mediated graft-versus-tumor effects. This
approach was initially developed by inducing the expression
of the herpes simplex 1 virus thymidine kinase (HSV-TK) in T
cells and by using Ganciclovir as a prodrug for elimination of
HSV-TK-expressing T cells. A phase I–II multicenter non-rando-
mized study of HSV-TK cell infusions after T-cell-depleted hap-
loidentical alloHSCT suggested that this therapy was feasible
and enhanced immune recovery while cases of GVHD could be
controlled by activating the suicide gene.[77] Concern about
the potential immunogenicity of HSV-TK protein led to the
development of alternative suicide gene therapies. These
include gene transfer of human CD20 and truncated human
EGFR polypeptide into T cells, which confer them sensitivity to
anti-CD20 and anti-EGFR antibodies, respectively. An inducible
system based on a fusion protein comprised of an extracellular
binding domain linked to human caspase-9 signaling domains
to deliver apoptotic signals in response to a chemical inducer
of dimerization (i.e. AP1903/Rimiducid) was also recently
Table 1. T-cell depleting approaches.
Drug or pathway Main mechanism of action
Level of clinical
evidence
Ongoing clinical studies for novel
therapies (ClinicalTrials.gov)
Anti-T-cell globulin (ATG) Donor T-cell depletion Phase III [63,64] Standard approach in the PBSC
setting
Alemtuzumab Depletion of CD52+ cells
(including donor T cells)
Phase I–II [71] –
Ex vivo CD34+ cell selection Ex vivo depletion of graft’s immune cells Phase II [74] –
Anti-CD2 monoclonal antibody (siplizumab) Donor T-cell depletion – Phase II: #NCT00113646
Pentostatin Apoptosis of donor T cells through inhibition
of adenosine deaminase
Phase I–II [76] Phase I: #NCT00096161
Suicide gene therapies: transducing T cells with herpes
simplex 1 virus thymidine kinase (HSV-TK), CD20,
EGF-R, inducible caspase (iCasp)
Donor T-cell depletion with specific molecules,






iCasp: phase I–II: #NCT01744223,
#NCT02065869
Post-transplant cyclophosphamide (Cy) Depletion of early proliferating alloreactive
donor T cells after graft infusion




Single-agent postransplant Cy: phase
III: #NCT02345850
Ex vivo photodepletion of anti-host reactive donor T
cells (TH9402, Kiadis)
Depletion of anti-host alloreactive donor T
cells
Phase II [80] Phase II: #NCT01794299
Ex vivo depletion of TCRαβ+ donor T cells Depletion of mature TCRαβ+ donor T cells






TCRαβ+/CD19+ depletion: phase II–III:
#NCT02323867, #NCT02600208
TCRαβ+ depletion: phase I–III:
#NCT02327351, #NCT02193880
Ex vivo depletion of CD45RA+ naive T cells Depletion of naive donor T cells, based on the
postulate that they are the main T-cell
subset mediating GVHD
Phase II [82] Phase II: #NCT 00914940,
#NCT02220985





























developed and provided promising results in a phase I clinical
trial in patients given T-cell depleted HLA-haploidentical
grafts.[78]
4.1.2. Depletion of proliferating, activated, alloreactive
donor T cells
Cyclophosphamide (Cy) is a nitrogen mustard alkylating agent
that mostly kills rapidly proliferating cells. Hence, Cy adminis-
tration early after transplant can be an efficient method to
specifically delete proliferating alloreactive T-cell clones while
sparing resting T cells and hematopoietic stem cells. Recent
findings also suggested that Tregs are relatively preserved
under Cy exposure, partly due to their higher expression of
aldehyde dehydrogenase.[83] Based on this evidence, the
John Hopkins University group investigated post-transplant
administration of high-dose Cy as a novel strategy for GVHD
prevention. They explored high-dose Cy (50 mg/kg, on days
+3 and +4) in combination with tacro/MMF (both started after
Cy administration) in patients transplanted with HLA-haploi-
dentical BM after a non-myeloablative conditioning regimen
combining fludarabine and 2 Gy total body irradiation (TBI).
Remarkably, they reported a very low incidence of grade III–IV
aGVHD (6%).[84] Similar results (10% incidence of grade III–IV
aGVHD) were recently observed using similar postgrafting
immunosuppression in the setting of myeloablative haploi-
dentical BM-alloHSCT.[85]
Investigators at the John Hopkins further assessed the
efficacy of high-dose Cy (50 mg/kg on days +3 and +4) as
the sole post-transplant GVHD prophylaxis after myeloablative
HLA-matched BM-alloHSCT, and reported a low incidence of
grade III–IV aGVHD (10%).[79] A 3-arm phase 3 study is cur-
rently ongoing, comparing post-transplant Cy to standard
tacro/MTX and to a CD34+ cell graft selection approach for
GVHD prophylaxis in HLA-matched myeloablative BM- or
PBSC-alloHSCT (ClinicalTrials.gov#NCT02345850) (Table 1).
Another approach to selectively deplete anti-host reactive
donor T cells has been developed.[86] It consists of ex vivo
donor T-cell activation against host antigens, and their subse-
quent selective elimination through a photodynamic purging
method. Specifically, donor T cells are cultured with allogeneic
cells in vitro in the presence of the photosensitizer 4,5-dibromor-
hodamine methyl ester (TH9402). If donor T cells are activated,
they retain TH9402, which becomes highly cytotoxic after expo-
sure to a fluorescent-light scanning device. Interestingly, this
method preserved pathogen- and tumor-specific T cells as well
as Tregs. Amulticenter phase II study is currently evaluating post-
transplant adoptive transfer of donor lymphocytes selectively
allodepleted of host-reactive T cells using this photodynamic
therapy, in the setting of haploidentical donor alloHSCT
(ClinicalTrials.gov#NCT01794299). Preliminary results were pre-
sented at the 2015 meeting of the American Society of
Hematology and suggested that this approach is safe, and asso-
ciated with a very low incidence of aGVHD (none of the 23
patients experienced grade III-IV aGVHD).[80]
4.1.3. Depletion of T-cell subtype(s)
Based on the observation that aGVHD could be prevented by
CD8-depletion of the graft in a number of murine models,
Nimer et al. assessed CD8-depletion of the graft as a way to
prevent aGVHD without promoting infections or compromis-
ing graft-versus-tumor effects.[87] In a randomized study
including 38 patients, CD8-depletion of BM from HLA-identical
siblings effectively prevented the incidence of grade II–IV
aGVHD (20% versus 80%, P = 0.004). Unfortunately, these
findings were not confirmed in another phase II randomized
study performed in patients given PBSC from HLA-matched
related or unrelated donors after nonmyeloablative condition-
ing.[88]
Attempts to improve immune reconstitution and graft-ver-
sus-tumor effect after T-cell depleted alloHSCT recently led to
the development of a new method of T-cell depletion based
on the specific elimination of mature T cells carrying α and β
chains of the TCR (αβ+ T cells) and preservation of donor-
derived NK cells and TCRγδ+ T cells in the graft.[89] This
approach was recently reported to efficiently prevent aGVHD
after HLA-haploidentical alloHSCT, without any need for post-
transplant pharmacologic prophylaxis [81] (Table 1).
Based on the postulate that GVHD-promoting T cells mainly
reside within the naive compartment (see above), several
groups have studied ex vivo graft depletion of naive donor T
cells to limit aGVHD. One of them relies on CD45RA+ cell
immunomagnetic depletion. This strategy was recently
assessed in a pilot trial in the setting of myeloablative PBSC-
alloHSCT.[82] Unfortunately, no reduction in the incidence of
aGVHD was observed as compared with historical controls, but
the incidence of cGVHD was remarkably infrequent (9% versus
50% in historical controls). This approach is currently further
assessed in a phase II study (ClinicalTrials.gov#NCT02220985).
4.2. Other pharmacological approaches
Main targets of the approaches represented in Table 2 are also
shown in Figure 1.
4.2.1. Functional inhibition of donor T-cell activation
4.2.1.1. Inhibition of TCR-mediated signaling pathways.
Blockade of the calcium-dependent TCR signal transduction
pathway with calcineurin inhibitors is universally used as
standard GVHD prophylaxis. As mentioned above, signal
transduction downstream to TCR activation also mediates
through the NFκB pathway. Proteasome inhibitors, such as
bortezomib, can block NFκB activation (by inhibiting the
degradation of its inhibitory protein IκBα) and were reported
to efficiently mitigate GVHD in preclinical studies.[99]
Moreover, by inhibiting degradation of many other intracel-
lular proteins, proteasome blockade may also affect T-cell
chemotactism, inflammatory cytokine secretion, APC func-
tions and promote Tregs.[99] Based on these observations,
the early addition of short-course bortezomib (on days +1,
+4, and +7 after alloHSCT) to standard tacro/MTX has been
assessed in phase I–II clinical trials and provided encoura-
ging results.[90,100] Combination of bortezomib with other
agents, such as tacro and sirolimus (#NCT00670423) or post-
transplant Cy (#NCT01860170), as well as use of the novel
proteasome inhibitor carfilzomib (#NCT01991301) are cur-
rently under investigation.
A selective inhibitor of NFκB, PS-1145, has also been
reported to efficiently prevent experimental aGVHD and to























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































have a superior therapeutic index compared with bortezomib,
enabling prolonged administration. Hence, this molecule may
constitute a viable therapeutic approach to reduce GVHD
severity.[101]
4.2.1.2. Costimulation blockade. Costimulatory signal
blockade to induce T-cell anergy has been the subject of
several preclinical studies.[26] Most of them were dedicated
to inhibition of B7:CD28 and CD40:CD40L interactions.
CTLA4-Ig (abatacept, belatacept) are recombinant proteins
composed of the extracellular domain of CTLA4 with the Fc
fragment of human immunoglobulin G1 (IgG1). CTLA4-Ig binds
to B7 proteins (CD80 and CD86) expressed on the surface of APCs,
thus making them unavailable for interaction with CD28 on T
cells. Preclinical studies suggested that CTLA4-Ig could reduce
GVHD.[26] Further, addition of abatacept to CSA/MTX standard
aGVHD prophylaxis was investigated in a pilot clinical trial invol-
ving 10 patients transplanted from unrelated donors.[91] Only
two patients developed grade II–IV acute GVHD. A phase II multi-
centre randomized trial of abatacept combined with calcineurin
inhibition and MTX after unrelated donor alloHSCT is currently
ongoing in the United States (ClinicalTrials.gov#NCT01743131).
Preclinical studies demonstrated that blockade of CD40:
CD40L interactions could reduce GVHD.[102] However, the
clinical application of anti-CD40L antibodies was prematurely
suspended since these agents were found to precipitate arter-
ial and venous thromboembolism, likely due to interactions
with CD40L-expressing activated platelets and endothelial
cells.
On the other hand, activation of inhibitory molecules (such
as PD1) may also result in anergization of alloreactive T cells.
Moreover, PD1 signaling could also convert Th1 cells into a
regulatory phenotype.[103] However, major limitation of such
approaches would be the probable simultaneous abrogation
of graft-versus-tumor effects.
4.2.1.3. Inhibition of IL-2- and other cytokine-induced sig-
nal transduction pathways. Inhibition of T-cell proliferation
in response to IL-2 by interfering with the mTOR pathway
(with mTOR inhibitors, such as sirolimus (siro) or everolimus)
has been explored as GVHD prevention for several years.
Impact of mTOR inhibitors on cell-cycle progression predomi-
nates in Tconvs while preserving Treg that depend on the
STAT-5 pathway for IL-2 signaling.[29,104] A recent large ran-
domized phase III trial compared postgrafting immunosup-
pression with tacro/siro to tacro/MTX in patients
transplanted from HLA-identical siblings after TBI-based mye-
loablative conditioning.[92] The authors observed similar
aGVHD incidence and aGVHD-free survival (primary endpoint)
but faster engraftment, and less mucosal toxicity with siro/
tacro. In contrast, use of sirolimus in patients given myeloa-
blative doses of busulfan is contraindicated because it is asso-
ciated with high incidence of sinusoidal obstruction syndrome.
[105] The use of siro for GVHD prophylaxis is also being
explored in a randomized study in the setting of RIC-
alloHSCT (ClinicalTrials.gov#NCT01428973). Blocking cytokine-
induced signal transduction in T cells by interfering with JAK/
STAT pathways is another emerging approach to attenuate
GVHD (Figure 1). In preclinical models, inhibition of JAK3 (i.e.
with tofacitinib [106]) or JAK1/2 (i.e. with ruxolitinib [107,108])
reduced aGVHD by impairing Th1 and Th17 differentiation,
and by increasing Tregs. A recent retrospective multicenter
study of 54 patients treated with ruxolitinib for cortico-refrac-
tory aGVHD reported encouraging results (81.5% overall
response, including 46.3% complete responses).[93] Based on
these data, ruxolitinib is currently being investigated for
aGVHD prevention in a clinical trial (#NCT02528877).
4.2.2. Gene expression modulation in T cells and other
immune cells (epigenetic modulators)
Gene expression is modulated through several epigenetic
pathways. For example, DNA methylation of gene promoters
can result in gene silencing. On the other hand, histone octa-
mers are major structural protein complexes that package
DNA into chromatin. Hence, covalent modification on the
amino terminal of the core histones (i.e. through acetylation,
methylation, ADP-ribosylation, phosphorylation, ubiquityla-
tion) can also affect chromatin assembly and therefore gene
accessibility for transcription. Epigenetic regulation of gene
expression in immune cells plays major role in orchestrating
their fate. Hence, DNA demethylation and histone deacetyla-
tion recently emerged as new promising strategies for GVHD
prevention (Figure 1).
Demethylating agents, such as 5-azacytidine (5-aza) and 5-
aza-2ʹ-deoxycytidine (decitabine) can be incorporated into
DNA and act as DNA methyltransferase (DNMT) inhibitors.
They are currently largely used for the treatment of myelodys-
plastic syndromes and acute myeloid leukemia. Further, mur-
ine studies have demonstrated that demethylating agents
prevented aGVHD by inhibiting the proliferation of Tconvs
and by inducing Treg (through the demethylation of the
FoxP3 gene/promoter).[109] De Lima et al. investigated low-
dose 5-aza in the post-transplant setting in patients with acute
myeloid leukemia or myelodysplastic syndrome, initially in an
attempt to prevent relapse.[110] They reported encouraging
results in terms of disease control, but also observed a low
incidence of aGVHD. Recently, in a phase I–II study, Goodyear
et al. reported that post-transplant 5-aza significantly
increased Treg numbers but also induced cytotoxic CD8+
T-cell response against several tumor antigens, thus poten-
tially preventing GVHD without compromising graft-versus-
tumor effects.[94] These promising results emphasize the
need to continue exploring demethylating agents for GVHD
prophylaxis in further prospective studies (Table 2).
Histone acetylation regulates gene expression by modulat-
ing DNA accessibility. Lysine residues at the amino-terminus of
histones are deacetylated by histone deacetylase enzymes
(HDACs). Hence, HDAC inhibition results in accumulation of
hyperacetylated histones and thus decreases gene accessibil-
ity for transcription. Moreover, emerging data also demon-
strate that HDACs can additionally target nonhistone cellular
proteins (such as STAT3), thereby modulating their function
and stability. Recently, HDAC inhibition with SAHA (vorinostat)
and ITF2357 (givinostat), that both mostly target class I and II
HDACs, have been shown to prevent experimental GVHD.[111]
On this basis, Choi et al. performed a phase I–II study investi-
gating the use of vorinostat (from day −10 to day +100) along
with tacro/MMF for aGVHD prevention after related donor





























alloHSCT, and reported a lower incidence of grade II–IV aGVHD
than expected (22% grade II–IV).[95] In agreement with pre-
clinical observations, treated patients had low serum levels of
inflammatory cytokines, high levels of IDO and high Treg
counts.[112] Phase II studies are currently exploring the addi-
tion of vorinostat to standard tacro-MTX in the unrelated
donor alloHSCT setting (#NCT01789255, #NCT01790568).
Importantly, it should be stressed that not all HDAC inhibitors
have similar effects on GVHD and, for example, the potent
HDAC inhibitor (LBH589, panobinostat) accelerated experi-
mental GVHD.[113]
4.2.3. Targeting extracellular mediators
4.2.3.1. Targeting cytokines and cytokine receptors. As
mentioned above, IL-2 is an essential cytokine for T-cell home-
ostasis. Blockade of IL-2 signaling with anti-IL-2 receptor
monoclonal antibodies (basiliximab and daclizumab) has
been investigated in several studies for controlling GVHD.
Unfortunately, IL-2 blockade increased GVHD-mortality in a
phase III study,[114] perhaps because of the negative impact
of IL-2 blockade on Tregs who depend on IL-2 for their home-
ostasis. In the opposite, a recent study has investigated the
administration of ultralow dose IL-2 (100,000–200,000 IU/m2 × 3
per week) after transplantation with the aim of promoting
Tregs and preventing GVHD.[115] Authors observed that IL-2
was well tolerated, expanded Tregs, and was associated with a
very low incidence of aGVHD (0/16 patients experienced grade
II–IV aGVHD).
Murine models have demonstrated an important role of IL-6
in the pathophysiology of aGVHD.[116] Based on these data, IL-6
inhibition with tocilizumab, an anti-IL-6 receptor monoclonal
antibody, has recently been assessed in a phase I–II clinical
trial.[96] Adding tocilizumab to standard GVHD prophylaxis
after HLA-matched donor alloHSCT resulted in low rate of
grade II–IV aGVHD (12%) compared to historical controls.
TNF-α is another important cytokine in aGVHD pathogen-
esis. Previous clinical reports have shown that a large
increase TNF-receptor-1 levels (a good surrogate for TNF-α
levels) early after the conditioning regimen predicted
aGVHD.[117,118] This evidence prompted investigations on
the efficacy of TNF-α inhibition for GVHD prevention.
Unfortunately, prospective studies showed that addition of
TNF-α inhibitors (infliximab or etanercept) to standard GVHD
failed to prevent aGVHD.[119] Similarly, a large phase III trial
showed that blockade of the proinflammatory cytokine IL-1
failed to prevent GVHD.[120] Finally, IL-21 has recently
emerged as a major inducer of Th1 and Th17 differentiation
and while administration of IL-21 inhibitors attenuated
GVHD in mice.[121] Several other cytokines (such as IL-17,
IL-12, IL-23, IL-22, IL-27, etc.) have also been implicated in
GVHD pathogenesis and their inhibition should also be eval-
uated in clinical trials.[27]
4.2.3.2. Targeting chemokine and chemokine receptors. T-
cell chemotaxis into target organs is mediated by chemokine-
and homing-receptors. A recent phase I-II study investigated
the addition of a CCR5 inhibitor (maraviroc) to tacro/MTX for
GVHD prophylaxis and demonstrated low incidence of grade
II–IV aGVHD (14.7%).[97] Additional phase II trials are currently
ongoing (Table 2). Other molecules, such as integrins, also play
pivotal roles in the homing of alloreactive cells to target
organs. Tissue specificity shown by integrins make them inter-
esting targets for future GVHD therapy.
4.2.3.3. Blocking ‘‘danger’’ signals. Administration of alpha
1-antitrypsin was shown to reduce heparan sulfate levels and
to prevent experimental GVHD.[122] Based on these observa-
tions, a pilot clinical trial of exogenous alpha 1-antitrypsin
supplementation in steroid-refractory GVHD is underway
(NCT01523821). However, to our knowledge, no study asses-
sing this strategy for GVHD prevention is currently ongoing.
Uric acid was also described as a potential DAMP in aGVHD.
Rasburicase is a recombinant urate-oxidase enzyme that cata-
lyzes the oxidation of uric acid into an inactive soluble meta-
bolite. In a phase I study of myeloablative alloHSCT, Yeh et al.
administrated rasburicase during the conditioning regimen
(0.2 mg/kg for five consecutive days) and observed a low
incidence of aGVHD (24% grade II–IV).[98]
In a similar concept, manipulation of gut microbiota to
reduce PAMP production has also been explored as a way to
attenuate GVHD. Gut decontamination with metronidazole or
ciprofloxacin during the peritransplant period seemed to con-
fer protection from aGVHD in patients given grafts from HLA-
identical siblings.[123] However, recent data suggesting a link
between loss of microbial diversity and intestinal aGVHD [23–
25] are now challenging the concept of gut antibiotic decon-
taminating strategies. Indeed, increased abundance of gut
commensal flora belonging to the Clostridiales and Blautia
species has been reported to be associated with reduced
lethal aGVHD and improved overall survival.[23–25] Hence,
novel strategies aimed at preserving such a ‘‘protective flora’’
might help preventing the development of aGVHD.
4.2.4. Targeting B cells
As mentioned above, B-cell involvement in the pathogenesis
of aGVHD has remained controversial. However, administra-
tion of the B-cell depleting agent rituximab before and after
alloHSCT is currently being explored in clinical trials
(#NCT01044745, #NCT01810926).
4.3. Cellular therapies to promote immune tolerance
Several cell subtypes are able to mediate immune tolerance.
Preclinical and early clinical data suggest that infusion or
modulation of immune regulatory cells will be important
tools for preventing GVHD in the future (see Table 3).
4.3.1. Regulatory T cells (Tregs)
Experimental studies have clearly demonstrated that infusion
of high doses of Tregs (one Treg for 1–2 CD4+ Tconv infused)
prevented murine and xenogeneic GVHD.[37,39] Based on
these observations, Treg infusion has been evaluated in the
clinical setting. Specifically, safety and efficacy of Treg infu-
sions were evaluated in a phase I clinical trial including 23
patients given double UCB-alloHSCT.[124] In that study, post-
transplant administration of escalated dose of in vitro
expanded Tregs (0.1–30 × 105 Tregs/kg, on day +1, ± day
+15) from a third-party UCB unit was safe and resulted in a





























decreased incidence of aGVHD as compared to historical con-
trols (43% versus 61%, P = 0.05).[124] Another pilot study of 28
patients transplanted from HLA-haploidentical donors ana-
lyzed whether pretransplant Treg infusions could allow coin-
fusion of CD34+ selected stem cells with Tconvs (to enhance
engraftment and immune recovery) at a dose that otherwise
causes fatal aGVHD.[130] In that study, Tregs were freshly
isolated from donors and infused at a dose of 2 × 106/kg
4 days before alloHSCT. Only two patients developed grade
II–IV aGVHD despite the absence of any postgrafting immuno-
suppressive therapy. More recently, the same group reported
the results of the first 43 patients with acute leukemia given
HLA-haploidentical Tregs as described earlier.[75] Only 6/41
patients (15%) developed grade II–IV aGVHD. At a median
follow-up of 46 months, only 2/41 evaluable patients had
relapsed, suggesting that this strategy of Treg + Tconv infu-
sion in the HLA-haploidentical setting increased graft-versus-
tumor effects without increasing GVHD.
Further efforts are directed at improving Treg manufactur-
ing and at determining which are the best Treg subsets for
Treg infusion.
4.3.2. MSCs
MSC may harbor a wide range of immunosuppressive proper-
ties. Moreover, due to the absence of HLA class I molecules on
their surface, MSC are hypoimmunogenic and can therefore be
transferred from third-party HLA-mismatched donors. A num-
ber of preclinical studies using various animal models have
assessed the efficacy of MSC to mitigate GVHD.[42] Results
were variable, with some studies having reported benefits
[131] while others having not.[132] Various factors, including
cell dose, timing of infusion, and pre-activated status of MSCs
might have added heterogeneity between studies and influ-
enced results. Pilot clinical studies have also suggested a
potential role for MSCs as GVHD prevention.[125,126]
Prospective randomized studies are currently underway in
order to more definitely assess the impact of MSC co-trans-
plantation on GVHD (Table 3).
4.3.3. Invariant natural killer T cells (iNKTs)
iNKT is another rare immunoregulatory T cell population, with
restricted T-cell receptors. Recent mouse experiments have
shown that infusion of in vitro expanded donor iNKT cells
attenuated experimental GVHD.[133] In patients, early post-
transplant recovery of donor-derived iNKT cells after alloHSCT
has been associated with reduced risk of aGVHD.[45]
Accordingly, high content of iNKT cells in the stem cell graft
has also been associated with a reduced risk of aGVHD.[127]
Thus, expanding iNKT (by in vivo or ex vivo manipulations)
might provide a new potential approach for controlling GVHD.
4.3.4. MDSCs
MDSCs are a heterogeneous population of immature myeloid
progenitors that have the ability to suppress effector T cell
responses and promote the development of Tregs. Several
mouse experiments have reported that adding functional
MDSCs in donor graft could alleviate aGVHD.[47,48] These
observations, however, remain to be confirmed in clinical trials.
4.4. Risk stratification directed strategy for aGVHD
prevention
Alternative approaches to decrease aGVHD-related morbidity and
mortality are focusing on the ability to predict aGVHD occurrence,
in an effort to provide an opportunity to abort aGVHD develop-
ment in patients at high risk for aGVHD by intensifying aGVHD
prophylaxis without exposing patients at low risk to undue toxicity
from excessive immunosuppressive therapy. Studies have identi-
fied clinical factors of aGVHD (i.e. age, type of donor, HLA-dispa-
rities, type of conditioning, pretransplant comorbidities), genetic
variants (i.e. NOD2 polymorphisms), and biomarkers (i.e. TNF
receptor-1 [TNFR1], IL-2 receptor [IL-2R], IL-8, hepatocyte growth
factor as well as, elafin regenerating islet-derived protein 3α
[REG3α] and suppressor of tumorigenicity 2 [ST2]) to correlate
with risks for aGVHD (nicely reviewed in Paczesny [134]) Hence,
it is possible to envision the future development of algorithms that
would predict risk of aGVHD for individual patients and would
further guide risk-adapted aGVHD prophylaxis.
5. Impact on cGVHD
Interestingly, some approaches for aGVHD prophylaxis also
result in mitigating cGVHD while others do not.[9] Current
Table 3. Cellular approaches.





Regulatory T cells (Tregs)
Treg infusion Promotion of immune tolerance Phase I–II [75,124] Phase I: #NCT01795573,
#NCT01937468
Phase II: #NCT02118311
Low dose IL-2 Promotion of Treg expansion and immune
tolerance
Phase I [115] Phase I: #NCT01937468
Phase II: #NCT01927120
Mesenchymal stem cells (MSCs)
MSC coinfusion Promotion of Tregs Phase I-II [125,126] Phase II: #NCT01045382
Invariant natural killer T (iNKT) cells
iNKT cell content in the graft Promotion of immune tolerance Retrospective study
[127]
Phase 0: # NCT02194868
Conditioning regimen involving total lymphoid
irradiation and ATG
Sparing of iNKT cells Phase II [128,129] Phase II: # NCT01566656,
#NCT00896493
Myeloid-derived suppressor cells (MDSCs)
MDSC infusion Promotion of immune tolerance Animal models
[47,48]
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knowledge concerning the impact of aGVHD prophylactic
strategies on cGVHD are summarized in Table 4.
6. Conclusion
Numerous novel approaches for aGVHD prevention are under-
going preclinical development or clinical testing based upon
the deeper understanding of the complex immunologic pro-
cesses involved in aGVHD. As Tconvs have been demonstrated
to play major role in aGVHD, donor T-cell depletion strategies
(e.g. with ATG, alemtuzumab, ex vivo CD34+ cell positive selec-
tion of the graft) have been investigated during the last
decades and have demonstrated potent efficacy for aGVHD
prevention. Thereafter, refined T-cell depleting approaches
progressively developed and still continue to emerge, aimed
at specifically targeting activated alloreactive T cells (e.g. post-
transplant Cy, suicide gene therapies, ex vivo photodepletion
of anti-host reactive donor T cells) or specific T cell subpopula-
tions (e.g. TCRαβ+, naive cells) while preserving immune recov-
ery and anti-tumor T cells. Some of them (e.g. post-transplant
Cy) already demonstrated potent efficacy in large prospective
trials. Other novel strategies aimed at functionally impairing
T-cell activation (e.g. proteasome inhibitors, costimulation
blockers, mTOR inhibitors), modulating T-cell fate (e.g. JAKs
inhibitors, demethylating agents, histone deacetylase inhibi-
tors) and interfering with homing properties (e.g. CCR5 inhibi-
tors) have also shown encouraging results for aGVHD
prevention. Approaches aimed at controlling the milieu to
make it less ``GVHD favorable’’ are also emerging, targeting
pro-inflammatory cytokines (e.g. anti-IL6 receptor antibody)
and danger signals (e.g. recombinant urate-oxidase and mod-
ulation of microbiota). In addition, Treg-based therapies to
promote immune tolerance have also demonstrated efficacy
to mitigate aGVHD in preclinical experiments as well as in
initial clinical studies. Other cell subsets such as iNKTs, MSCs,
and MDSCs were also recently reported to mediate immune
tolerance after alloHSCT and are currently under investigation
for aGVHD prevention. The ultimate step would likely be to
provide a risk-stratified strategy for aGVHD prevention, with
intensified prophylactic regimens (e.g. by using and/or com-
bining novel approaches) for patients at high risk for aGVHD
and alleviated prophylaxis for patients at low risk in a way to
avoid them undue toxicity from excessive immunosuppressive
therapy.
7. Expert opinion
New understanding in aGVHD pathogenesis will likely lead to
new standards for aGVHD prophylaxis in the future. According
to our opinion, the most promising novel pharmacological
approaches for aGVHD prophylaxis include post-transplant
Cy administration, HDAC inhibitors (such as vorinostat), pro-
teasome inhibitors (such as bortezomib) as well as IL-6 block-
ade (as example with tocilizumab). Further, although they
have not been assessed in phase II studies for GVHD preven-
tion yet, JAKs inhibitors (such as the JAK 1–2 inhibitor ruxolu-
tinib) and hypomethylating agents (such as azacitidine) are
also promising. In addition, the blocking of other cytokines
such as IL-21 deserves also to be investigated in appropriate
phase I–II studies.
The most promising novel cellular approach for aGVHD
prevention in our view consists of Treg co-transplantation.
Importantly, this approach seems to prevent aGVHD without
affecting graft-versus-tumor effects, both in murine models of
GVHD and in humans.[38,75] Current challenges for Treg ther-
apy include the difficulty to infuse a sufficient number of
Tregs, with a good purity, and to ensure that infused cells
persist and keep an immunoregulatory profile in the host. The
Table 4. Impact of aGVHD prophylactic strategies on cGVHD.
Strategy Results on GVHD Reference
Current strategies
Calcineurin inhibitor ± methotrexate (MTX) Little/no impact [9]
Calcineurin inhibitor + mycophenolate mofetil (MMF) Little/no impact [9]
Anti-T cell globulin (ATG) Decreased incidence [63,64]
Alemtuzumab Decreased incidence [67]
Ex vivo CD34+ cell selection Decreased incidence [74]
Novel strategies
Pentostatin Unknown –
Suicide gene therapy in T cells Decreased incidencea [77]
Post-transplant cyclophosphamide (Cy) Decreased incidence [79]
Ex vivo photodepletion of anti-host reactive donor T cells (TH9402, Kiadis) Unknown –
Ex vivo depletion of TCRαβ+ donor T cells Decreased incidencea [81]
Ex vivo depletion of CD45RA+ naive T cells Decreased incidencea [82]
Proteasome inhibitors (bortezomib) Decreased incidencea [90]
CTLA-4 immunoglobulin Unknown –
mTOR inhibitors (sirolimus) Little/no impact [92]
JAKs inhibitors Unknown –
Demethylating agents (5-azacytidine) Decreased incidencea [94]
Histone deacetylase inhibitors Unknown –
Anti-IL-6 receptor antibody (tocilizumab) Unknown –
CCR5 inhibitor (maraviroc) Unknown –
Recombinant urate-oxidase (rasburicase) Unknown –
Anti-CD20 antibody (rituximab) Decreased incidence [9]
Treg infusion Unknown –
Low dose IL-2 Unknown –
MSC coinfusion Unknown –
aThese results have to be validated in further studies.





























utility of adding low-doses of IL-2 to donor Treg infusion
remains to be investigated, especially in patients on calci-
neurin inhibitors.
Besides pharmacological and cellular therapies, modulation
of the microbiome will also likely play an important role in the
prevention of gut GVHD in the future.
An important limitation in the field has been the difficulty to
translate discoveries made in mouse-to-mouse models of GVHD
directly into clinical practice. This is partly due to differences
between human and murine immune systems, and more impor-
tantly, to the large genetic diversity within the human species in
contrast to what is present in inbred mice. Recent developments
in humanized models of GVHD may provide additional tool for
testing new immunoregulatory approaches on human immune
cells in vivo and offers the possibility to assess various donors
with different genetic background,[39,40,49] while the canine
model of unrelated dog-leukocyte antigen-mismatched trans-
plantation has remained the only animal model that allows
direct translation to the clinic.[55]
The holy grail of GVHD prophylaxis is to efficiently prevent
grade >1 aGVHD without compromising post-transplant
immune recovery and graft-versus-tumor effects.
Unfortunately, besides possibly the use of low-doses of ATG
on the one hand, and of donor Treg infusion in the other
hand, the vast majority of approaches that decrease GVHD in
humans also impair graft-versus-tumor effects. This is in contrast
to what has been observed in mouse-to-mouse models of GVHD
where a number of approaches are able to differentiate GVHD
and graft-versus-tumor effects. This can be probably explained
by the fact that many successful therapeutic interventions in
mouse-to-mouse models of aGVHD are efficient in CD4-depen-
dent GVHD models, while the graft-versus-tumor effect systems
used are largely mediated by CD8+ T cells.[18]
In the future, we can envision that the ultimate step for ideal
aGVHD prophylaxis would be an individualized approach, in
which the type and intensity of the immune suppression
would be dictated by algorithms evaluating the type of trans-
plantation and the risks for aGVHD determined by both pre-
transplant genetic testing and early post-transplant biomarkers.
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